The Arab Drug Company

CASE:ADCI Stock Report

Market Cap: ج.م857.8m

Arab Drug Past Earnings Performance

Past criteria checks 3/6

Arab Drug's earnings have been declining at an average annual rate of -0.6%, while the Pharmaceuticals industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 9.8% per year. Arab Drug's return on equity is 25.9%, and it has net margins of 11.6%.

Key information

-0.6%

Earnings growth rate

6.0%

EPS growth rate

Pharmaceuticals Industry Growth9.8%
Revenue growth rate9.8%
Return on equity25.9%
Net Margin11.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Arab Drug makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CASE:ADCI Revenue, expenses and earnings (EGP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24828961020
30 Jun 2478688980
31 Mar 24730761010
31 Dec 23723801000
30 Sep 2367167980
30 Jun 2363471990
31 Dec 2254980910
30 Sep 2251578840
30 Jun 2250576810
31 Dec 2152693820
30 Sep 2153296830
30 Jun 21537101820
31 Mar 21527104760
31 Dec 20540106760
30 Sep 20544106750
30 Jun 2052193730
31 Mar 2052482750
31 Dec 1949466710
30 Sep 1945652690
30 Jun 1943643660
31 Mar 1941543900
31 Dec 1840343910
30 Sep 1840142680
30 Jun 1838339600
31 Mar 1837945200
31 Dec 173714390
30 Sep 1735839230
30 Jun 1733935220
31 Mar 1731528240
31 Dec 1629022240
30 Sep 1626217250
30 Jun 1625014250
31 Mar 162406240
31 Dec 152315230
30 Sep 152255220
30 Jun 152245220
31 Mar 152233230
31 Dec 142203230
30 Sep 142154210
30 Jun 142063200
31 Mar 141943180
31 Dec 131841180

Quality Earnings: ADCI has a high level of non-cash earnings.

Growing Profit Margin: ADCI's current net profit margins (11.6%) are higher than last year (10%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ADCI's earnings have declined by 0.6% per year over the past 5 years.

Accelerating Growth: ADCI's earnings growth over the past year (42%) exceeds its 5-year average (-0.6% per year).

Earnings vs Industry: ADCI earnings growth over the past year (42%) exceeded the Pharmaceuticals industry 37.9%.

Return on Equity

High ROE: Whilst ADCI's Return on Equity (25.89%) is high, this metric is skewed due to their high level of debt.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:17
End of Day Share Price 2024/12/22 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

The Arab Drug Company is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mohamed HamzaPharos Research